Alerts will be sent to your verified email
Verify Email
THEMISMED
|
Themis Medicare
|
NGL Fine-Chem
|
Hester Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
3.26 % | 1.8 % | 1.91 % |
|
Financials
|
|||
|
5 yr Average ROE
|
15.48 % | 18.68 % | 10.99 % |
|
5yr average Equity Multiplier
|
1.56 | 1.37 | 2.14 |
|
5yr Average Asset Turnover Ratio
|
0.71 | 1.03 | 0.46 |
|
5yr Avg Net Profit Margin
|
13.75 % | 12.56 % | 11.57 % |
|
Price to Book
|
2.96 | 3.25 | 4.81 |
|
P/E
|
0.0 | 43.95 | 40.22 |
|
5yr Avg Cash Conversion Cycle
|
62.99 Days | 24.74 Days | 60.38 Days |
|
Inventory Days
|
69.58 Days | 47.94 Days | 100.79 Days |
|
Days Receivable
|
159.79 Days | 84.83 Days | 89.02 Days |
|
Days Payable
|
137.27 Days | 83.75 Days | 127.62 Days |
|
5yr Average Interest Coverage Ratio
|
7.27 | 25.7 | 6.96 |
|
5yr Avg ROCE
|
17.31 % | 24.83 % | 11.14 % |
|
5yr Avg Operating Profit Margin
|
18.07 % | 18.08 % | 22.71 % |
|
5 yr average Debt to Equity
|
0.28 | 0.16 | 0.75 |
|
5yr CAGR Net Profit
|
-3.53 % | -18.08 % | -4.4 % |
|
5yr Average Return on Assets
|
9.9 % | 13.76 % | 5.28 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
67.15 % | 72.74 % | 53.73 % |
|
Share Pledged by Promoters
|
2.43 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.03 % | -1.07 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -0.03 % |
|
Themis Medicare
|
NGL Fine-Chem
|
Hester Biosciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Verticals
|
Verticals
|
-
|
-
|